Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

EPAD 2017 - Tit Albreht

139 views

Published on

Will the new Joint Action include PCa? Cancon’s vision
Tit Albreht, Coordinator EU Joint Action on Cancer Control (Cancon)

Published in: Health & Medicine
  • Be the first to comment

EPAD 2017 - Tit Albreht

  1. 1. Will the new Joint Action include Prostate Cancer? CANCON’s vision Tit Albreht National Institute of Public Health of Slovenia
  2. 2. In the Joint Action (JA) CanCon prostate cancer was a part of the discussions concerning (potential) screening programmes and as an index cancer for the description of after-care pathways. Indirectly, it was included in the discussions on the Comprehensive Cancer Control Networks (CCCNs) and on Survivorship.
  3. 3. Existence of guidelines for certain cancers and for their after-care Cancer location Number of guidelines Countries with guidelines Specific to after-care* No. of guidelines with at least one scientific reference to after-care** Guide for GPs Breast 24 19 7 17 4 Colorectal ca. 21 16 6 12 1 Lung 17 11 3 9 1 Melanoma 15 13 1 12 1 Prostate 18 14 4 14 1 Source: European Guide for Quality Improvement in Comprehensive Cancer Control. www.cancercontrol.eu
  4. 4. Recurrence detection [18] • Physical diagnostic tests [14] • Diagnostic imaging [8] • Awareness [13] Laboratory diagnostic tests [18] • Risk of recurrence/new cancer [5] • Organisation of care [7] • Signs of recurrence [10] • Pathological diagnostic tests [5] Long-term effects [11] • Potential complications [11] • Treatment of complications [7] • Psychological support [4] Recurrence prevention [2] • Physical activity [2] • Nutrition [2] • Weight management [1] • Alcohol consumption [1] • Smoking cessation [2] Existence of guidelines for prostate cancer and for its after-care
  5. 5. Existence of guidelines for prostate cancer and for its after-care
  6. 6. New screening programmes require step-wise decision-making which includes the establishment of evidence of effectiveness, benefits that outweigh the harms and cost-effectiveness. Once evidence exists to support these criteria, implementation research in each country is needed to assess the feasibility of fulfilling the national requirements in practice. In light of currently available evidence, some prostate cancer screening policies may be cost-effective but questions remain on the optimal benefit-harm balance. Forthcoming results of European trials are expected to inform policy-making on lung cancer screening in Europe. New trials need to be financed to investigate optimal strategies for gastric cancer screening. Key message on screening recommendations and potential prostate cancer screening (Message 4)
  7. 7. Structure of the new Joint Action WP 1 – Coordination, WP 2 – Dissemination, WP 3 – Evaluation WP 4 - Roadmap on Implementation and Sustainability of Cancer Control Actions WP 5 – Cancer prevention WP 6 – Genomics in Cancer Control and Care WP 7 – Cancer Information and Registries WP 8 – Challenges in Cancer Care WP 9 – Innovative Therapies in Cancer WP 10 – Governance of Integrated and Comprehensive Cancer Care New Joint Action iPAAC (Innovative Partnership for Action Against Cancer)
  8. 8. New Joint Action iPAAC (Innovative Partnership for Action Against Cancer) Where would prostate cancer be present? WP4 – Roadmap on the Implementation and Sustainability for the Cancer Control Actions WP5 – Prevention Screening – innovation and proposal of more effective solutions of population-based screening programmes and risk stratification Early detection strategies and management
  9. 9. The new JA iPAAC will further develop early detection and screening strategies for the cancers that have so far not been supported by guidelines. WPs on challenges in cancer care and innovative therapies will touch upon all cancers. New Joint Action iPAAC (Innovative Partnership for Action Against Cancer)

×